All posts by: Michael Zand

Bidding war erupts over Dimension’s gene therapy pipeline as Ultragenyx counters Regenxbio deal
Endpoints News
A bidding war has suddenly erupted over one of the most damaged biotechs in gene therapy R&D. Just weeks after Regenxbio lined up the acquisition of Dimension Therapeutics $DMTX for , $86 million in stock, Ultragenyx $RARE has come along with an …

Brammer Bio Completes Expansion of Cell and Gene Therapy …
PR Newswire (press release)
CAMBRIDGE, Mass., Sept. 18, 2017 /PRNewswire/ — Brammer Bio (“Brammer”), a cell and gene therapy contract development and manufacturing organization …

and more »

Brammer Bio Completes Expansion of Cell and Gene Therapy Clinical Manufacturing Facilities in Florida
Markets Insider
CAMBRIDGE, Mass., Sept. 18, 2017 /PRNewswire/ — Brammer Bio (“Brammer”), a cell and gene therapy contract development and manufacturing organization (CDMO), today announced completion of its clinical capacity expansion in Alachua, Florida.

and more »

Cells Programmed Like Computers to Fight Disease
Newswise (press release)
Cells can be programmed like a computer to fight cancer, influenza, and other serious conditions – thanks to a breakthrough in synthetic biology by the University of Warwick. Newswise — Led by Professor Alfonso Jaramilloin the School of Life Sciences …

Cells Programmed Like Computers to Fight Disease
Newswise (press release)
Cells can be programmed like a computer to fight cancer, influenza, and other serious conditions – thanks to a breakthrough in synthetic biology by the University of Warwick. Newswise — Led by Professor Alfonso Jaramilloin the School of Life Sciences …

and more »

UK biotech round-up: Autolus joins CAR–T race, Horizon’s new CRISPR tech, Allergy Therapeutics’ grass gambit
pharmaphorum
“BCMA CAR–T cell therapies have shown considerable promise in early clinical studies. A dual-targeted approach may minimise the risk for antigen negative escape and extend CAR-T treatment to patients with low density of BCMA antigen on the surface …
Syncona’s Autolus begins three T-cell cancer trials | Digitallook.comDIGITALLOOK
Arix Bioscience plc notes positive clinical study announcements from Autolus LimitedMarkets Insider
Arix Bioscience Notes Autolus Ltd’s Updates On Clinical Progress …London South East (registration) (blog)
Stock Market Wire
all 4 news articles »

UK biotech round-up: Autolus joins CAR–T race, Horizon’s new CRISPR tech, Allergy Therapeutics’ grass gambit
pharmaphorum
“BCMA CAR–T cell therapies have shown considerable promise in early clinical studies. A dual-targeted approach may minimise the risk for antigen negative escape and extend CAR-T treatment to patients with low density of BCMA antigen on the surface …
Syncona’s Autolus begins three T-cell cancer trials | Digitallook.comDIGITALLOOK
Arix Bioscience plc notes positive clinical study announcements from Autolus LimitedMarkets Insider
Arix Bioscience Notes Autolus Ltd’s Updates On Clinical Progress …London South East (registration) (blog)
Stock Market Wire
all 4 news articles »